Glaukos Corporation (GKOS)
NYSE: GKOS · Real-Time Price · USD
159.34
+2.95 (1.89%)
Jan 21, 2025, 4:00 PM EST - Market closed
Glaukos Revenue
Glaukos had revenue of $96.67M in the quarter ending September 30, 2024, with 23.86% growth. This brings the company's revenue in the last twelve months to $360.35M, up 18.70% year-over-year. In the year 2023, Glaukos had annual revenue of $314.71M with 11.26% growth.
Revenue (ttm)
$360.35M
Revenue Growth
+18.70%
P/S Ratio
22.58
Revenue / Employee
$397,295
Employees
907
Market Cap
8.78B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 314.71M | 31.85M | 11.26% |
Dec 31, 2022 | 282.86M | -11.15M | -3.79% |
Dec 31, 2021 | 294.01M | 69.05M | 30.70% |
Dec 31, 2020 | 224.96M | -12.03M | -5.07% |
Dec 31, 2019 | 236.98M | 55.71M | 30.73% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
GKOS News
- 7 days ago - Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform - Business Wire
- 21 days ago - Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday - Benzinga
- 4 weeks ago - Glaukos Submits New Drug Application to U.S. FDA for Epioxa™ - Business Wire
- 4 weeks ago - Glaukos: Still Bullish, But Embedded Expectations Are Now High - Seeking Alpha
- 5 weeks ago - Glaukos Announces Participation in the J.P. Morgan Healthcare Conference - Business Wire
- 7 weeks ago - Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos - Benzinga
- 2 months ago - Glaukos Announces Participation in Upcoming Investor Conferences - Business Wire
- 2 months ago - Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds - Benzinga